TMC buys tranScrip out of administration, saving 45 jobs
What's the deal? TMC Pharma ServicesDealroom has a profile for this one. Try Dealroom → has acquired the business and assets of tranScripDealroom has a profile for this one. Try Dealroom →, a specialist pharmaceutical consultancy, via a pre-pack administration process. The deal transfers tranScrip's roughly 45 employees to TMC and secures continuity for its customers. Terms were not disclosed.
The players: tranScrip, headquartered in Berkshire with operations in Ireland, supports biotech and small pharma companies with expert drug development capabilities for complex programmes. TMC, established in 2001, is a global pharma services company operating across the UK, US and Ireland, plus a contractor network spanning more than 70 countries.
Why now? The sale was completed through administration. Rick Harrison and Howard Smith of InterpathDealroom has a profile for this one. Try Dealroom → were appointed joint administrators to tranScrip Limited on August 14, 2026, while Eamonn Richardson and Kieran Wallace were named joint receivers over tranScrip Ireland LimitedDealroom has a profile for this one. Try Dealroom → the same day.
What's the endgame? TMC offers end-to-end drug development, from early-phase consulting and clinical development to market access and commercialisation. tranScrip's medical, clinical and regulatory expertise complements those services.
What could go wrong? Pre-pack administrations move fast and can strain client and staff confidence. Integrating tranScrip's team and relationships without disruption will be key to retaining value.
Simon Estcourt, chief executive officer of TMC, said the combination "strengthens our ability to support clients throughout the development lifecycle while creating new opportunities for growth and collaboration."
Harrison noted that tranScrip "has played an important role in the innovation and commercialisation of new medicines, including treatments for Covid-19, as well as immunological and gene therapies."
The signal: The rescue underscores continued consolidation among pharma services firms, as buyers absorb distressed specialist consultancies to broaden their end-to-end drug development offering.
Read more: Interpath
Image credit: UK in Sweden
